SCHEMBL745355

SCHEMBL745355

CCOC(=O)n1nc(NC(=O)c2ccc(F)cc2)c2c(C(=O)NC(C)(C)c3ccccc3)csc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
PTGER4 P35408 1/20 0.39
POLB P06746 1/20 0.38
BRAF P15056 1/20 0.37
PPARG P37231 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 2/20 0.36
ADORA3 P0DMS8 2/20 0.36
ADORA2A P29274 2/20 0.36
ADORA1 P30542 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL746264 0.92 LMNA (0.41) LMNAKDM4EPOLBBRAFALDH1A1
SCHEMBL6438233 0.87 AURKA (0.43) LMNAKDM4EALDH1A1MAPTNPC1
SCHEMBL4633164 0.82 ABL1 (0.44) LMNAKDM4EPTGER4BRAFPPARG
SCHEMBL4632612 0.75 ADORA2A (0.41) LMNAKDM4EBRAFALDH1A1CYP1A2
SCHEMBL741094 0.72 ABL1 (0.48) LMNAKDM4EPOLBPPARGALDH1A1
SCHEMBL1433977 0.70 ABL1 (0.41) LMNAKDM4EPOLBALDH1A1L3MBTL1
SCHEMBL1433978 0.70 ABL1 (0.46) LMNAKDM4EPOLBPPARGMAPT
SCHEMBL739466 0.69 AURKA (0.51) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL742843 0.69 LMNA (0.47) LMNAKDM4EBRAFALDH1A1CYP1A2
SCHEMBL738735 0.69 KDM4E (0.43) LMNAKDM4EPOLBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors MAP3K19, MAP3K1, MAP3K3 LMNA 3398/4885KDM4E 1432/4885PTGER4 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.